Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wockhardt's Total Liabilities for the quarter that ended in Mar. 2026 was ₹33,340 Mil.
Wockhardt's quarterly Total Liabilities
declined
from Sep. 2025 (₹36,570.00 Mil) to Dec. 2025 (₹0.00 Mil) but then
increased
from Dec. 2025 (₹0.00 Mil) to Mar. 2026 (₹33,340.00 Mil).
Wockhardt's annual Total Liabilities
declined
from Mar. 2024 (₹39,870.00 Mil) to Mar. 2025 (₹34,780.00 Mil) and
declined
from Mar. 2025 (₹34,780.00 Mil) to Mar. 2026 (₹33,340.00 Mil).
The historical data trend for Wockhardt's Total Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
Wockhardt's Total Liabilities for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Total Liabilities of ₹33,340 Mil mean?
Wockhardt (NSE:WOCKPHARMA) has a Total Liabilities of ₹33,340 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Wockhardt and its competitors.
Is Wockhardt's Total Liabilities too high?
Wockhardt's current Total Liabilities is ₹33,340 Mil. Overall, Wockhardt has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wockhardt's Total Liabilities compare to ZTS?
Wockhardt's Total Liabilities of ₹33,340 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Wockhardt and its competitors. Wockhardt's current Total Liabilities is ₹33,340 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wockhardt stock overvalued right now?
Based on GuruFocus' analysis, Wockhardt (NSE:WOCKPHARMA) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,247.67, compared to a current price of ₹2,021.00 — trading 62% above its estimated fair value. The current Total Liabilities is ₹33,340 Mil. Wockhardt's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Wockhardt (NSE:WOCKPHARMA), the current Total Liabilities is ₹33,340 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wockhardt (NSE:WOCKPHARMA) Overvalued in 2026?
Based on GuruFocus' analysis, Wockhardt stock appears to be overvalued.
The current stock price of ₹2,021.00 is trading 62% above its estimated GF Value™ of ₹1,247.67.
GuruFocus considers Wockhardt to be Significantly Overvalued.
Key valuation signals for NSE:WOCKPHARMA:
Total Liabilities: ₹33,340 Mil
GF Value™: ₹1,247.67 vs. price of ₹2,021.00 (62% above fair value)
No single metric tells the full story. See the NSE:WOCKPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wockhardt Ltd is a drug manufacturing company focusing on pharmaceutical and biotechnology products. The group is involved in new drug discovery, contract manufacturing, API, vaccines, and branded pharmaceuticals business. In addition, it operates a chain of super-specialty hospitals. Its novel antibiotic platform has various assets, such as Zaynich (WCK 5222); Miqnaf (Nafithromycin), a macrolide-class respiratory antibiotic; Ertapenem-Zidebactam (WCK 6777); Foviscu (WCK 2482), an antibiotic for Gram-negative infections; and Odrate (WCK 6777), among others. The group is mainly engaged in the pharmaceutical business, which is considered its only reportable business segment. Geographically, it generates maximum revenue from Europe, followed by India, the USA, and the Rest of the world.
60GF Score
Get the complete analysis for NSE:WOCKPHARMA
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:WOCKPHARMA has been successfully added to your 
